Global Cord Blood Gross Profit

The latest gross profit for CO is $1B as of July 2022. That compares with $1B in the prior-year period — up 3.7% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Global Cord Blood's historical trend and sector peers before judging valuation or financial health.

Over the past year, CO's gross profit moved from $1B to $1B — a 3.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Global Cord Blood's operating scale or balance-sheet position.

Against Healthcare companies, CO currently prints $1B for gross profit, while the sector average sits near $66B. That is roughly 98.4% below the sector mean. Large gaps often invite a closer look at Global Cord Blood's growth, margins, and balance sheet.

A gross profit figure of $1B for CO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting CO's gross profit ($1B), review year-over-year change from $1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.